| A long-term ERT being developed by Amicus Therapeutics for the treatment of Pompe disease |
| Received its first approval on 27 March 2023 in the EU |
| Approved for use in combination with miglustat for the treatment of adults with late-onset Pompe disease |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.